Premium
The GP2 peptide: A HER2/ neu ‐based breast cancer vaccine
Author(s) -
Clive Kevin S.,
Tyler Josh A.,
Clifton G. Travis,
Holmes Jarrod P.,
Ponniah Sathibalan,
Peoples George E.,
Mittendorf Elizabeth A.
Publication year - 2012
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21723
Subject(s) - medicine , trastuzumab , peptide vaccine , clinical trial , monoclonal antibody , breast cancer , peptide , immunotherapy , her2/neu , oncology , cancer , antibody , immunology , epitope , biochemistry , chemistry
Preclinical studies suggest that GP2, a HER2/ neu ‐derived peptide, is immunogenic. Subsequent phase I clinical trials demonstrated that GP2‐based vaccines are safe and effective in stimulating peptide‐specific immunity. A GP2 peptide vaccine is currently being evaluated in a phase II efficacy trial enrolling breast cancer patients. This article reviews initial studies characterizing GP2, clinical trials investigating GP2‐based vaccines, and novel immunotherapy strategies incorporating GP2 in combination with other peptides or with the monoclonal antibody trastuzumab. J. Surg. Oncol. 2012; 105:452–458. © 2012 Wiley Periodicals, Inc.